Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy

Journal of the American Geriatrics Society

Volumn 59, Issue 5, 2011, Pages 827-836

  Dworkin, Robert H ^a   Panarites, Christopher J ^b   Armstrong, Edward P ^c,d   Malone, Daniel C ^c,d   Pham, Sissi V ^e  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NeurogesX Inc   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Strategic Therapeutics LLC   (United States)

^e Sissi Pham Consulting Inc   (United States)

Author keywords

diabetic peripheral neuropathy; healthcare costs; healthcare utilization; neuropathic pain; postherpetic neuralgia

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; DEXTROMETHORPHAN; HYPNOTIC SEDATIVE AGENT; KETAMINE; LIDOCAINE; MEMANTINE; MEXILETINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; RETROSPECTIVE STUDY;

AGED; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETIC NEUROPATHIES; FEMALE; HEALTH SERVICES FOR THE AGED; HEALTH SERVICES RESEARCH; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79955999769     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03403.x     Document Type: Article

References (57)

1. Treede R-D, Jensen TS, Campbell JN, et al,. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635.
2. Dworkin RH, Johnson RW, Breuer J, et al,. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl 1): S1-S26. (Pubitemid 44956795)
3. Schmader KE., Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18: 350-354. (Pubitemid 35291575)
4. Boulton AJM, Malik RA, Arezzo JC, et al,. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486. (Pubitemid 38680000)
5. Boulton AJM, Vinik AI, Arezzo JC, et al,. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
6. Barrett AM, Lucero MA, Le T, et al,. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med 2007; 8 (Suppl 2): S50-S62. (Pubitemid 47288511)
7. Attal N, Cruccu G, Haanpää M, et al,. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153-1169. (Pubitemid 44581463)
8. Dworkin RH, O'Connor AB, Backonja M, et al,. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132: 237-251.
9. Moulin DE, Clark AJ, Gilron I, et al,. Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007; 12: 13-21.
10. Dworkin RH, O'Connor A, Audette J, et al,. Recommendations for the pharmacologic management of neuropathic pain: An overview and literature update. Mayo Clinic Proc 2010; 85 (Suppl): S3-S14.
11. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, et al,. Peripheral neuropathic pain: A multidimensional burden for patients. Eur J Pain 2001; 5: 379-389.
12. McDermott AM, Toelle TR, Rowbotham DJ, et al,. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 2006; 10: 127-135.
13. Jensen MP, Chodroff MJ, Dworkin RH., The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology 2007; 68: 1178-1182. (Pubitemid 46608464)
14. O'Connor AB., Neuropathic pain: Quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009; 27: 95-112.
15. Berger A, Dukes EM, Oster G., Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 143-149. (Pubitemid 38879392)
16. Dworkin RH, White R, O'Connor AB, et al,. Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007; 55: 1168-1175. (Pubitemid 47106670)
17. Dworkin RH, White R, O'Connor AB, et al,. Healthcare expenditure burden of persisting herpes zoster pain. Pain Med 2008; 9: 348-353. (Pubitemid 351467890)
18. Dworkin RH, Malone DC, Panarites CJ, et al,. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010; 11: 360-368.
19. Lachaine J, Gordon A, ChoiniÃre M, et al,. Painful neuropathic disorders: An analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manage 2007; 12: 31-37.
20. Rodriguez MJ, Garcia AJ., A registry study of the aetiology and costs of neuropathic pain in pain clinics: Results of the Registry of aEtiologies and Costs (REC) in Neuropathic Pain Disorders Study. Clin Drug Invest 2007; 27: 771-782.
21. Stein AN, Britt H, Harrison C, et al,. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27: 520-529.
22. Gore M, Dukes E, Rowbotham DJ, et al,. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007; 11: 652-664. (Pubitemid 46818059)
23. Torrance N, Smith BH, Watson MC, et al,. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam Pract 2007; 24: 481-485. (Pubitemid 350142646)
24. Dieleman JP, Kerklaan J, Huygen FJPM, et al,. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008; 137: 681-688.
25. Oster G, Harding G, Dukes E, et al,. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain 2005; 6: 356-363. (Pubitemid 40804340)
26. Gore M, Brandenburg NA, Hoffman DL, et al,. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 2006; 7: 892-900. (Pubitemid 44854739)
27. Tölle T, Xu X, Sadosky AB., Painful diabetic neuropathy: A cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006; 20: 26-33.
28. Van Seventer R, Sadosky A, Lucero M, et al,. A cross-sectional survey of health State impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35: 132-137.
29. Taylor RS., Epidemiology of refractory neuropathic pain. Pain Practice 2006; 6: 22-26. (Pubitemid 43732685)
30. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
31. Gibbons CH, Griffin JW, Polydefkis M, et al,. The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy. Neurology 2006; 66: 256-258. (Pubitemid 43970168)
32. England JD, Gronseth GS, Franklin G, et al,. Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Muscle Nerve 2009; 39: 106-115.
33. Vo T, Rice ASC, Dworkin RH., Non-steroidal anti-inflammatory drugs and neuropathic pain: How do we explain continued widespread use? Pain 2009; 143: 169-171.
34. Wu CL, Marsh A, Dworkin RH., The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87: 121-129. (Pubitemid 30621444)
35. Kumar V, Krone K, Mathieu A., Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: An appraisal of current evidence. Reg Anesth Pain Med 2004; 29: 454-461. (Pubitemid 39221893)
36. Cruccu G, Aziz TZ, Garcia-Larrea L, et al,. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007; 14: 952-970. (Pubitemid 47300786)
37. Dubinsky RM, Miyasaki J., Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 173-176.
38. Dworkin RH, Gnann JW, Oaklander AL, et al,. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9 (Suppl 1): S37-S44.
39. Gauthier A, Breuer J, Carrington D, et al,. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47.
40. Garnett GP, Ferguson NM., Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol 1996; 6: 151-161. (Pubitemid 26297192)
41. Schuette MC, Hethcote HW., Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 1999; 61: 1031-1064.
42. Brisson M, Edmunds WJ, Gay NJ., Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003; 70 (Suppl 1): S31-S37.
43. Thomas SL, Hall AJ., What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26-33. (Pubitemid 38057055)
44. Yih WK, Brooks DR, Lett SM, et al,. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5: 68.
45. Russell ML, Schopflocher DP, Svenson L, et al,. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007; 135: 908-913. (Pubitemid 47616471)
46. Reynolds MA, Chaves SS, Harpaz R, et al,. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: A review. J Infect Dis 2008; 197 (Suppl 2): S224-S227. (Pubitemid 351590175)
47. Rimland D, Moanna A., Increasing incidence of herpes zoster among veterans. Clin Infect Dis 2010; 50: 1000-1005.
48. Oxman MN, Levin MJ, Johnson GR, et al,. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
49. Schmader K, Gnann JW, Watson CP., The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197 (Suppl 2): S207-S215. (Pubitemid 351590173)
50. Morbidity and mortality weekly report: State-specific incidence of diabetes among adults: Participating states, 1995-1997 and 2005-2007. MMWR Morbid Mortal Wkly Rep 2008; 57: 1169-1173.
51. Bouhassira D, Lantéri-Minet M, Attal LB, et al,. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136: 380-387. (Pubitemid 351680253)
52. Dworkin RH, McDermott MP, Raja SN., Preventing chronic postsurgical pain: How much of a difference makes a difference? Anesthesiology 2010; 112: 516-518.
53. O'Connor AB, Noyes K, Holloway RG., A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007; 55: 1176-1184. (Pubitemid 47106676)
54. O'Connor AB, Noyes K, Holloway RG., A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 2008; 26: 1045-1064.
55. Gilron I, Johnson AP., Economics of chronic pain: How can science guide health policy? Can J Anesth 2010; 57: 530-538.
56. Hornberger J, Robertus K., Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145: 317-325. (Pubitemid 46768588)
57. Pellissier JM, Brisson M, Levin MJ., Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 49: 8326-8337. (Pubitemid 350087379)